

Munich, 21 June 2021

GÖRG advises Heidelberg Pharma AG on a private placement with gross proceeds of EUR 20 million

GÖRG Partnerschaft von Rechtsanwälten mbB advised Heidelberg Pharma AG on a capital increase with gross proceeds of EUR 20 million under the leadership of Munich partner Dr. Bernt Paudtke.

The capital increase based on resolutions of 15 June 2021 represents approximately 10% of the company's outstanding share capital and will increase the total number of shares to 34,173,009. The 3,106,637 new shares were placed exclusively with ew biotech specialist institutional investors, including Polar Capital Biotech Investment Fund, Invus and DH-LT-Investments GmbH, an investment company of Mr. Dietmar Hopp, amongst others, via an accelerated book building transaction and will be admitted to trading on the Frankfurt Stock Exchange. The issue price was EUR 6.44 per share, resulting in gross proceeds of EUR 20 million for Heidelberg Pharma AG.

The capital increase has been executed by Bryan, Garnier & Co acting as global coordinator and sole bookrunner.

Advisors Heidelberg Pharma

GÖRG Partnerschaft von Rechtsanwälten mbB

Dr. Bernt Paudtke, Partner, M&A / Corporate, Munich

Dr. Christian Glauer, Associated Partner, M&A / Corporate, Munich

Tobias Reichenberger, Associate, M&A / Corporate, Munich

Legal Department Heidelberg Pharma AG

Mikaela Dimitropoulos (Director Legal, HR & IP)

Advisors Bryan, Garnier & Co

Pinsent Masons Partnerschaft von Rechtsanwälten mbB

Dr. Susanne Lenz, LL.M. (University of Pennsylvania), Partner, M&A / Corporate, Frankfurt am Main

Dušan Stojković, Senior Associate, M&A / Corporate, Frankfurt am Main

Sara Šepac, Associate, M&A / Corporate, Frankfurt am Main

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6.

Your contact at GÖRG

Dr. Bernt Paudtke

Phone +49 89 3090667-0, E-Mail: bpaudtke@goerg.de

Communications & Marketing

Benjamin Kuthning
Phone +49 221 33660-161, E-Mail: bkuthning@goerg.de

About GÖRG

GÖRG is one of Germany's leading and independent business law firms.

With more than 300 lawyers and tax advisors in Berlin, Cologne, Frankfurt am Main, Hamburg and Munich, we advise well-known domestic and foreign businesses from all areas of industry, banking, real estate, trade, media and services on all core areas of business law.

Our Offices

GÖRG Partnerschaft von Rechtsanwälten mbB

BERLIN

Kantstraße 164, 10623 Berlin
Phone +49 30 884503-0, Fax +49 30 882715-0

HAMBURG

Alter Wall 20 – 22, 20457 Hamburg
Phone +49 40 500360-0, Fax +49 40 500360-99

COLOGNE

Kennedyplatz 2, 50679 Cologne
Phone +49 221 33660-0, Fax +49 221 33660-80

MUNICH

Prinzregentenstraße 22, 80538 Munich
Phone +49 89 3090667-0, Fax +49 89 3090667-90

FRANKFURT AM MAIN

Ulmenstraße 30, 60325 Frankfurt am Main
Phone +49 69 170000-17, Fax +49 69 170000-27